Sarah A Lyons1, Mareen R Datema2, Thuy-My Le3, Riccardo Asero4, Laura Barreales5, Simona Belohlavkova6, Frédéric de Blay7, Michael Clausen8, Ruta Dubakiene9, Cristina Fernández-Perez5, Philipp Fritsche10, David Gislason8, Karin Hoffmann-Sommergruber11, Monika Jedrzejczak-Czechowicz12, Laurian Jongejan13, Marek L Kowalski12, Tanya Z Kralimarkova14, Jonas Lidholm15, Nikolaos G Papadopoulos16, Bo Pontoppidan15, Todor A Popov17, Nayade Del Prado5, Ashok Purohit18, Isabel Reig19, Suranjith L Seneviratne20, Athanasios Sinaniotis21, Emilia Vassilopoulou22, Serge A Versteeg13, Stefan Vieths23, Aeilko H Zwinderman24, Paco M J Welsing25, E N Clare Mills21, Barbara K Ballmer-Weber26, André C Knulst3, Montserrat Fernández-Rivas27, Ronald Van Ree28. 1. Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. Electronic address: s.a.lyons-2@umcutrecht.nl. 2. Department of Experimental Immunology, Amsterdam University Medical Centers, Location AMC, Amsterdam, The Netherlands; Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam University Medical Center, Amsterdam, The Netherlands. 3. Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. 4. Ambulatorio di Allergologia, Clinica San Carlo, Paderno Dugnano, Italy. 5. Clinical Epidemiology Unit, Preventive Medicine Department, Hospital Clinico San Carlos, IdISSC, Madrid, Spain. 6. Medical Faculty and Faculty Hospital Pilsen, Charles University, Pilsen, Czech Republic. 7. Allergy Division, Chest Disease Department, Strasbourg University Hospital, University of Strasbourg, Strasbourg, France. 8. Landspitali University Hospital, Faculty of Medicine, University of Iceland, Reykjavik, Iceland. 9. Medical Faculty, Vilnius University, Vilnius, Lithuania. 10. Allergy Unit, Department of Dermatology, University Hospital of Zürich, Zürich, Switzerland. 11. Medical University of Vienna, Department of Pathophysiology and Allergy Research, Vienna, Austria. 12. Department of Immunology, Rheumatology and Allergy, Faculty of Medicine, Medical University of Łódź, Łódź, Poland. 13. Department of Experimental Immunology, Amsterdam University Medical Centers, Location AMC, Amsterdam, The Netherlands. 14. Clinical Centre of Allergology, Medical University of Sofia, Sofia, Bulgaria. 15. Thermo Fisher Scientific, Uppsala, Sweden. 16. Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece; Division of Infection, Immunity & Respiratory Medicine, Manchester Institute of Biotechnology, University of Manchester, Manchester, United Kingdom. 17. University Hospital Sv. Ivan Rilski, Sofia, Bulgaria. 18. Allergy Division, Chest Disease Department, Strasbourg University Hospital, Strasbourg, France. 19. Allergy Department, Hospital Clinico San Carlos, IdISSC, Madrid, Spain. 20. Institute of Immunity and Transplantation, University College London, London, United Kingdom. 21. Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece. 22. Department of Nutritional Sciences and Dietetics, International Hellenic University, Thessaloniki, Greece. 23. Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Langen, Germany. 24. Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam University Medical Center, Amsterdam, The Netherlands. 25. Division of Internal Medicine and Dermatology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. 26. Medical Faculty, Vilnius University, Vilnius, Lithuania; Faculty of Medicine, University of Zürich, Zürich, Switzerland; Clinic for Dermatology and Allergology, Kantonsspital St Gallen, St Gallen, Switzerland. 27. Allergy Department, Hospital Clinico San Carlos, IdISSC, ARADyAL, Madrid, Spain. 28. Department of Experimental Immunology, Amsterdam University Medical Centers, Location AMC, Amsterdam, The Netherlands; Department of Otorhinolaryngology, Amsterdam University Medical Centers, Location AMC, Amsterdam, The Netherlands.
Abstract
BACKGROUND: Walnut allergy is common across the globe, but data on the involvement of individual walnut components are scarce. OBJECTIVES: To identify geographical differences in walnut component sensitization across Europe, explore cosensitization and cross-reactivity, and assess associations of clinical and serological determinants with severity of walnut allergy. METHODS: As part of the EuroPrevall outpatient surveys in 12 European cities, standardized clinical evaluation was conducted in 531 individuals reporting symptoms to walnut, with sensitization to all known walnut components assessed in 202 subjects. Multivariable Lasso regression was applied to investigate predictors for walnut allergy severity. RESULTS: Birch-pollen-related walnut sensitization (Jug r 5) dominated in Northern and Central Europe and lipid transfer protein sensitization (Jug r 3) in Southern Europe. Profilin sensitization (Jug r 7) was prominent throughout Europe. Sensitization to storage proteins (Jug r 1, 2, 4, and 6) was detected in up to 10% of subjects. The walnut components that showed strong correlations with pollen and other foods differed between centers. The combination of determinants best predicting walnut allergy severity were symptoms upon skin contact with walnut, atopic dermatitis (ever), family history of atopic disease, mugwort pollen allergy, sensitization to cat or dog, positive skin prick test result to walnut, and IgE to Jug r 1, 5, 7, or carbohydrate determinants (area under the curve = 0.81; 95% CI, 0.73-0.89). CONCLUSIONS: Walnut-allergic subjects across Europe show clear geographical differences in walnut component sensitization and cosensitization patterns. A predictive model combining results from component-based serology testing with results from extract-based testing and information on clinical background allows for good discrimination between mild to moderate and severe walnut allergy.
BACKGROUND: Walnut allergy is common across the globe, but data on the involvement of individual walnut components are scarce. OBJECTIVES: To identify geographical differences in walnut component sensitization across Europe, explore cosensitization and cross-reactivity, and assess associations of clinical and serological determinants with severity of walnut allergy. METHODS: As part of the EuroPrevall outpatient surveys in 12 European cities, standardized clinical evaluation was conducted in 531 individuals reporting symptoms to walnut, with sensitization to all known walnut components assessed in 202 subjects. Multivariable Lasso regression was applied to investigate predictors for walnut allergy severity. RESULTS: Birch-pollen-related walnut sensitization (Jug r 5) dominated in Northern and Central Europe and lipid transfer protein sensitization (Jug r 3) in Southern Europe. Profilin sensitization (Jug r 7) was prominent throughout Europe. Sensitization to storage proteins (Jug r 1, 2, 4, and 6) was detected in up to 10% of subjects. The walnut components that showed strong correlations with pollen and other foods differed between centers. The combination of determinants best predicting walnut allergy severity were symptoms upon skin contact with walnut, atopic dermatitis (ever), family history of atopic disease, mugwort pollen allergy, sensitization to cat or dog, positive skin prick test result to walnut, and IgE to Jug r 1, 5, 7, or carbohydrate determinants (area under the curve = 0.81; 95% CI, 0.73-0.89). CONCLUSIONS: Walnut-allergic subjects across Europe show clear geographical differences in walnut component sensitization and cosensitization patterns. A predictive model combining results from component-based serology testing with results from extract-based testing and information on clinical background allows for good discrimination between mild to moderate and severe walnut allergy.
Authors: Sebastian Führer; Anna S Kamenik; Ricarda Zeindl; Bettina Nothegger; Florian Hofer; Norbert Reider; Klaus R Liedl; Martin Tollinger Journal: Sci Rep Date: 2021-02-18 Impact factor: 4.379
Authors: Mareen R Datema; Sarah A Lyons; Montserrat Fernández-Rivas; Barbara Ballmer-Weber; André C Knulst; Riccardo Asero; Laura Barreales; Simona Belohlavkova; Frédéric de Blay; Michael Clausen; Ruta Dubakiene; Cristina Fernández-Perez; Philipp Fritsche; David Gislason; Karin Hoffmann-Sommergruber; Monika Jedrzejczak-Czechowicz; Laurian Jongejan; Marek L Kowalski; Tanya Z Kralimarkova; Jonas Lidholm; Nikolaos G Papadopoulos; Todor A Popov; Nayade Del Prado; Ashok Purohit; Isabel Reig; Suranjith L Seneviratne; Athanassios Sinaniotis; Emilia Vassilopoulou; Serge A Versteeg; Stefan Vieths; Paco M J Welsing; E N Clare Mills; Thuy-My Le; Aeilko H Zwinderman; Ronald van Ree Journal: Front Allergy Date: 2021-06-07
Authors: Paul J Turner; Stefania Arasi; Barbara Ballmer-Weber; Alessia Baseggio Conrado; Antoine Deschildre; Jennifer Gerdts; Susanne Halken; Antonella Muraro; Nandinee Patel; Ronald Van Ree; Debra de Silva; Margitta Worm; Torsten Zuberbier; Graham Roberts Journal: Allergy Date: 2022-04-28 Impact factor: 14.710